Related Experiment Videos
An overview of antiarrhythmic drug management of electrical storm
1Cardiovascular Division, The Lankenau Hospital, Wynnewood, PA 19096, USA. prkowey@mem.po.com
Insights
Intravenous amiodarone effectively treats electrical storm, a life-threatening heart arrhythmia. Studies show it is as effective as bretylium with fewer side effects, offering a safer treatment option for patients.
Area of Science:
- Cardiology
- Electrophysiology
- Pharmacology
Background:
- Electrical storm is a lethal cardiac arrhythmia characterized by recurrent ventricular fibrillation or tachycardia.
- It often affects older men with coronary artery disease, post-myocardial infarction, or cardiac surgery.
- Conventional antiarrhythmic drugs are frequently ineffective for electrical storm management.
Purpose of the Study:
- To evaluate the efficacy and safety of intravenous amiodarone in treating electrical storm.
- To compare intravenous amiodarone with intravenous bretylium for electrical storm management.
Main Methods:
- Review of three recent studies involving critically ill patients with electrical storm.
- Two studies investigated varying doses of intravenous amiodarone.
- One study compared intravenous amiodarone to intravenous bretylium.
Main Results:
- Intravenous amiodarone demonstrated effectiveness in treating electrical storm.
- Amiodarone was found to be as effective as bretylium.
- Significantly fewer adverse effects requiring discontinuation were observed with amiodarone compared to bretylium.
- Common side effects included hypotension and bradycardia, manageable by infusion rate adjustment.
- Proarrhythmia was infrequently observed.
Conclusions:
- Intravenous amiodarone is an effective and safer alternative for managing electrical storm.
- It offers a favorable side effect profile compared to bretylium.
- Further research may explore optimal dosing strategies.
Abstract:
Electrical storm, the most lethal of all cardiac arrhythmias, is defined as incessant or frequently recurrent ventricular fibrillation, or hemodynamically destabilizing ventricular tachycardia. Electrical storm typically develops in older men with coronary artery disease, in the setting of a acute myocardial infarction or following cardiac surgery. Treatment of electrical storm with conventional antiarrhythmic drugs is seldom effective. Amiodarone, an anti-arrhythmic agent with established efficacy in the treatment of a variety of atrial and ventricular tachyarrhythmias, is now available as an intravenous formulation in hospitals. Three recent studies have examined the effect of intravenous amiodarone in the management of electrical storm. The studies, performed in critically ill patients, found amiodarone to be effective in the treatment of these serious arrhythmias. Two of the studies compared different dose ranges for intravenous amiodarone, while one study compared amiodarone to intravenous bretylium. The investigators found amiodarone to be as effective as bretylium, and to have significantly fewer adverse effects requiring drug discontinuation. Side effects of intravenous amiodarone included hypotension and bradycardia, both of which were managed by reducing the rate of the infusion. Proarrhythmia, defined as torsade de pointes or new onset ventricular fibrillation, was infrequently seen in the studies.